Hyperglycemia-induced effects on glycocalyx components in the retina.
Animals
Blood Glucose
/ metabolism
Blotting, Western
Cells, Cultured
Diabetes Mellitus, Experimental
/ metabolism
Diabetes Mellitus, Type 1
/ metabolism
Diabetic Retinopathy
/ metabolism
Endothelial Cells
/ drug effects
Enzyme-Linked Immunosorbent Assay
Glucose
/ pharmacology
Glycocalyx
/ metabolism
Glypicans
/ metabolism
Hyaluronan Receptors
/ metabolism
Hyperglycemia
/ metabolism
Insulin
/ blood
Male
Mass Spectrometry
RNA, Messenger
/ genetics
Rats
Rats, Wistar
Real-Time Polymerase Chain Reaction
Retina
/ metabolism
Retinal Vessels
/ cytology
Syndecans
/ metabolism
CD44
Diabetes
Endothelial cells
Glycocalyx
Glypicans
Hyperglycemia
Retina
Syndecans
Journal
Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
27
08
2021
revised:
10
11
2021
accepted:
12
11
2021
pubmed:
22
11
2021
medline:
28
12
2021
entrez:
21
11
2021
Statut:
ppublish
Résumé
Diabetic retinopathy is a vision-threatening complication of diabetes characterized by endothelial injury and vascular dysfunction. The loss of the endothelial glycocalyx, a dynamic layer lining all endothelial cells, contributes to several microvascular pathologies, including an increase in vascular permeability, leukocyte plugging, and capillary occlusion, and may drive the progression of retinopathy. Previously, a significant decrease in glycocalyx thickness has been observed in diabetic retinas. However, the effects of diabetes on specific components of the retinal glycocalyx have not yet been studied. Therefore, the aim of our study was to investigate changes in synthesis, expression, and shedding of retinal glycocalyx components induced by hyperglycemia, which could provide a novel therapeutic target for diabetic retinopathy. Primary rat retinal microvascular endothelial cells (RRMECs) were grown under normal glucose (5 mM) or high-glucose (25 mM) conditions for 6 days. The mRNA and protein levels of the glycocalyx components were examined using qRT-PCR and Western blot analysis, respectively. Further, mass spectrometry was used to analyze protein intensities of core proteins. In addition, the streptozotocin-induced Type 1 diabetic rat model was used to study changes in the expression of the retinal glycocalyx in vivo. The shedding of the glycocalyx was studied in both culture medium and in plasma using Western blot analysis. A significant increase in the shedding of syndecan-1 and CD44 was observed both in vitro and in vivo under high-glucose conditions. The mRNA levels of syndecan-3 were significantly lower in the RRMECs grown under high glucose conditions, whereas those of syndecan-1, syndecan-2, syndecan-4, glypican-1, glypican-3, and CD44 were significantly higher. The protein expression of syndecan-3 and glypican-1 in RRMECs was reduced considerably following exposure to high glucose, whereas that of syndecan-1 and CD44 increased significantly. In addition, mass spectrometry data also suggests a significant increase in syndecan-4 and a significant decrease in glypican-3 protein levels with high glucose stimulation. In vivo, our data also suggest a significant decrease in the mRNA transcripts of syndecan-3 and an increase in mRNA levels of glypican-1 and CD44 in the retinas of diabetic rats. The diabetic rats exhibited a significant reduction in the retinal expression of syndecan-3 and CD44. However, the expression of syndecan-1 and glypican-1 increased significantly in the diabetic retina. One of the main findings of our study was the considerable diversity of glucose-induced changes in expression and shedding of various components of endothelial glycocalyx, for example, increased endothelial and retinal syndecan-1, but decreased endothelial and retinal syndecan-3. This indicates that the reported decrease in the retinal glycocalyx in diabetes in not a result of a non-specific shedding mechanism. Moreover, mRNA measurements indicated a similar diversity, with increases in endothelial and/or retinal levels of syndecan-1, glypican-1, and CD44, but a decrease for syndecan-3, with these increases in mRNA potentially a compensatory reaction to the overall loss of glycocalyx.
Identifiants
pubmed: 34801534
pii: S0014-4835(21)00412-7
doi: 10.1016/j.exer.2021.108846
pmc: PMC8665121
mid: NIHMS1759609
pii:
doi:
Substances chimiques
Blood Glucose
0
Glypicans
0
Hyaluronan Receptors
0
Insulin
0
RNA, Messenger
0
Syndecans
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108846Subventions
Organisme : NEI NIH HHS
ID : R01 EY025632
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Proc Natl Acad Sci U S A. 2012 May 1;109(18):7049-54
pubmed: 22499789
Diabetologia. 2019 Mar;62(3):517-530
pubmed: 30612136
Circ Res. 2005 Mar 18;96(5):488-500
pubmed: 15774861
Cardiovasc Diabetol. 2012 Sep 22;11:113
pubmed: 22998723
Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1541-7
pubmed: 12855481
Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):389-98
pubmed: 25359392
Pflugers Arch. 2007 Jun;454(3):345-59
pubmed: 17256154
Dis Markers. 2015;2015:796052
pubmed: 26420915
PLoS One. 2019 May 15;14(5):e0214737
pubmed: 31091226
Am J Physiol Heart Circ Physiol. 2016 Jul 1;311(1):H168-76
pubmed: 27199117
J Appl Physiol (1985). 2007 Jun;102(6):2251-9
pubmed: 17347383
Diabetes. 2006 Apr;55(4):1127-32
pubmed: 16567538
Blood. 2010 Mar 25;115(12):2449-57
pubmed: 20097882
Biophys J. 2017 Jul 11;113(1):101-108
pubmed: 28700908
J Nutr Biochem. 2017 Feb;40:219-227
pubmed: 27951474
Curr Eye Res. 1997 Feb;16(2):127-30
pubmed: 9068943
Arthritis Res Ther. 2019 Jul 12;21(1):172
pubmed: 31300004
Mol Biol Cell. 2008 Jul;19(7):2789-801
pubmed: 18417614
Arterioscler Thromb Vasc Biol. 2021 Apr;41(4):1374-1389
pubmed: 33596666
Regul Pept. 2005 Jan 15;124(1-3):221-4
pubmed: 15544863
Am J Physiol Heart Circ Physiol. 2019 Mar 1;316(3):H647-H663
pubmed: 30632766
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1135-41
pubmed: 11923257
Microcirculation. 2020 Feb;27(2):e12596
pubmed: 31628816
Integr Biol (Camb). 2014 Mar;6(3):338-47
pubmed: 24480876
Diabetes Res Clin Pract. 2009 Nov;86(2):83-8
pubmed: 19735958
Mol Med Rep. 2013 Sep;8(3):829-36
pubmed: 23846350
J Cell Mol Med. 2015 Jun;19(6):1366-74
pubmed: 25702768
Front Endocrinol (Lausanne). 2020 Sep 04;11:591
pubmed: 33013692
Front Oncol. 2013 Dec 19;3:310
pubmed: 24392351
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
J Diabetes Complications. 2004 Sep-Oct;18(5):300-8
pubmed: 15337504
Front Immunol. 2020 Jan 09;10:3031
pubmed: 31998313
Int J Mol Sci. 2018 Jun 20;19(6):
pubmed: 29925789
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
J Invest Dermatol. 2009 Jun;129(6):1321-4
pubmed: 19434087
J Biol Chem. 2008 Dec 19;283(51):35435-44
pubmed: 18957427
Acta Diabetol. 2013 Apr;50(2):111-5
pubmed: 20683626
Lab Invest. 2000 Jan;80(1):37-45
pubmed: 10653001
Biomaterials. 2016 Jul;94:45-56
pubmed: 27101205
Oxid Med Cell Longev. 2018 Apr 10;2018:9045976
pubmed: 29849922
Am J Pathol. 2001 Jan;158(1):147-52
pubmed: 11141487
Brain Res Mol Brain Res. 2000 Apr 14;77(1):125-30
pubmed: 10814838
Front Endocrinol (Lausanne). 2020 Nov 18;11:603450
pubmed: 33312163
Graefes Arch Clin Exp Ophthalmol. 2007 Oct;245(10):1523-32
pubmed: 17653754
Am J Physiol Heart Circ Physiol. 2014 Feb;306(3):H363-72
pubmed: 24285115
J Biol Chem. 2003 May 2;278(18):16045-53
pubmed: 12591930
F1000Res. 2013 Dec 09;2:270
pubmed: 24555114
Diabetes. 2006 Feb;55(2):480-6
pubmed: 16443784
Acta Med Okayama. 2010 Oct;64(5):277-83
pubmed: 20975760
Arthritis Res Ther. 2014 Jul 11;16(4):R148
pubmed: 25015005
J Biol Chem. 1991 Dec 5;266(34):22939-47
pubmed: 1744087
J Biol Chem. 1999 Apr 16;274(16):10816-22
pubmed: 10196157
Kidney Int. 2020 May;97(5):951-965
pubmed: 32037077
Am J Physiol Endocrinol Metab. 2019 Dec 1;317(6):E973-E983
pubmed: 31550181
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Exp Mol Med. 2018 Apr 6;50(4):1-11
pubmed: 29622771
Microcirculation. 2020 Jul;27(5):e12617
pubmed: 32125048
PLoS One. 2015 Jan 24;10(1):e0117404
pubmed: 25617766
Nat Commun. 2019 May 7;10(1):2124
pubmed: 31064993
Eur J Nutr. 2006 Oct;45(7):369-75
pubmed: 16810465
Prog Retin Eye Res. 2015 Sep;48:160-80
pubmed: 25936649
Invest Ophthalmol Vis Sci. 2013 Apr 26;54(4):2992-9
pubmed: 23572104
Invest Ophthalmol Vis Sci. 2019 Feb 1;60(2):748-760
pubmed: 30793207
PLoS One. 2013 Nov 18;8(11):e78954
pubmed: 24260138
J Biol Chem. 2010 Jan 1;285(1):555-64
pubmed: 19875451
Exp Cell Res. 2016 Nov 1;348(2):184-189
pubmed: 27688027
Cancer Res. 2004 Feb 1;64(3):876-82
pubmed: 14871815
Exp Clin Endocrinol Diabetes. 2014 Jan;122(1):44-9
pubmed: 24464597
PLoS One. 2011 Feb 22;6(2):e17312
pubmed: 21364956
FASEB J. 2020 Oct;34(10):13125-13139
pubmed: 32830349
Invest Ophthalmol Vis Sci. 2015 Dec;56(13):8239-47
pubmed: 26720478
Compr Physiol. 2020 Jul 8;10(3):933-974
pubmed: 32941691
Sichuan Da Xue Xue Bao Yi Xue Ban. 2010 Nov;41(6):980-5
pubmed: 21265098
Cardiovasc Diabetol. 2016 Jan 29;15:18
pubmed: 26822858
Cancer Res. 2020 Mar 15;80(6):1342-1356
pubmed: 31969374
Curr Hypertens Rep. 2004 Apr;6(2):85-9
pubmed: 15010009
Circulation. 2000 Apr 4;101(13):1500-2
pubmed: 10747340
Exp Eye Res. 2019 Jul;184:213-220
pubmed: 31028750
Diabetologia. 2010 Dec;53(12):2646-55
pubmed: 20865240
Exp Eye Res. 2019 Feb;179:125-131
pubmed: 30445048